vs
Dominari Holdings Inc.（DOMH）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Dominari Holdings Inc.的1.0倍（$30.3M vs $30.1M），REGENXBIO Inc.净利率更高（-221.3% vs -438.1%，领先216.8%），Dominari Holdings Inc.同比增速更快（220.4% vs 43.0%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 39.4%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DOMH vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$30.1M
营收增速更快
DOMH
高出177.4%
43.0%
净利率更高
RGNX
高出216.8%
-438.1%
两年增速更快
DOMH
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $30.3M |
| 净利润 | $-131.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -8.9% | -190.0% |
| 净利率 | -438.1% | -221.3% |
| 营收同比 | 220.4% | 43.0% |
| 净利润同比 | -12426.2% | -31.2% |
| 每股收益（稀释后） | $-6.94 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHRGNX
| Q4 25 | $30.1M | $30.3M | ||
| Q3 25 | $50.8M | $29.7M | ||
| Q2 25 | $34.1M | $21.4M | ||
| Q1 25 | $8.1M | $89.0M | ||
| Q4 24 | $9.4M | $21.2M | ||
| Q3 24 | $4.0M | $24.2M | ||
| Q2 24 | $6.2M | $22.3M | ||
| Q1 24 | $1.4M | $15.6M |
净利润DOMHRGNX
| Q4 25 | $-131.8M | $-67.1M | ||
| Q3 25 | $125.2M | $-61.9M | ||
| Q2 25 | $16.6M | $-70.9M | ||
| Q1 25 | $-32.5M | $6.1M | ||
| Q4 24 | $1.1M | $-51.2M | ||
| Q3 24 | $-4.2M | $-59.6M | ||
| Q2 24 | $-6.1M | $-53.0M | ||
| Q1 24 | $-5.4M | $-63.3M |
毛利率DOMHRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DOMHRGNX
| Q4 25 | -8.9% | -190.0% | ||
| Q3 25 | -3.1% | -176.3% | ||
| Q2 25 | -57.0% | -296.3% | ||
| Q1 25 | -394.6% | 13.6% | ||
| Q4 24 | 0.4% | -242.1% | ||
| Q3 24 | -79.1% | -256.6% | ||
| Q2 24 | -44.3% | -251.3% | ||
| Q1 24 | -205.2% | -408.8% |
净利率DOMHRGNX
| Q4 25 | -438.1% | -221.3% | ||
| Q3 25 | 246.4% | -208.3% | ||
| Q2 25 | 48.7% | -331.8% | ||
| Q1 25 | -400.5% | 6.8% | ||
| Q4 24 | 11.4% | -241.3% | ||
| Q3 24 | -104.2% | -246.3% | ||
| Q2 24 | -99.1% | -237.7% | ||
| Q1 24 | -398.0% | -405.4% |
每股收益（稀释后）DOMHRGNX
| Q4 25 | $-6.94 | $-1.30 | ||
| Q3 25 | $7.27 | $-1.20 | ||
| Q2 25 | $1.12 | $-1.38 | ||
| Q1 25 | $-3.02 | $0.12 | ||
| Q4 24 | $0.21 | $-0.99 | ||
| Q3 24 | $-0.67 | $-1.17 | ||
| Q2 24 | $-1.01 | $-1.05 | ||
| Q1 24 | $-0.91 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $69.4M | $102.7M |
| 总资产 | $112.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOMHRGNX
| Q4 25 | $80.5M | $230.1M | ||
| Q3 25 | $176.2M | $274.2M | ||
| Q2 25 | $28.2M | $323.3M | ||
| Q1 25 | $18.9M | $267.9M | ||
| Q4 24 | $8.2M | $234.7M | ||
| Q3 24 | $7.2M | $255.5M | ||
| Q2 24 | $12.1M | $290.4M | ||
| Q1 24 | $7.1M | $338.7M |
股东权益DOMHRGNX
| Q4 25 | $69.4M | $102.7M | ||
| Q3 25 | $210.2M | $161.5M | ||
| Q2 25 | $88.6M | $213.7M | ||
| Q1 25 | $42.4M | $274.2M | ||
| Q4 24 | $39.9M | $259.7M | ||
| Q3 24 | $38.3M | $301.4M | ||
| Q2 24 | $42.4M | $348.3M | ||
| Q1 24 | $47.7M | $390.7M |
总资产DOMHRGNX
| Q4 25 | $112.9M | $453.0M | ||
| Q3 25 | $223.4M | $525.2M | ||
| Q2 25 | $109.3M | $581.0M | ||
| Q1 25 | $52.3M | $490.9M | ||
| Q4 24 | $47.1M | $466.0M | ||
| Q3 24 | $43.4M | $519.1M | ||
| Q2 24 | $49.1M | $569.4M | ||
| Q1 24 | $52.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DOMHRGNX
| Q4 25 | $22.7M | $-52.3M | ||
| Q3 25 | $-4.9M | $-56.0M | ||
| Q2 25 | $-353.0K | $-49.3M | ||
| Q1 25 | $1.2M | $33.6M | ||
| Q4 24 | $-16.7M | $-31.6M | ||
| Q3 24 | $-4.7M | $-40.5M | ||
| Q2 24 | $1.4M | $-45.5M | ||
| Q1 24 | $-8.6M | $-55.5M |
自由现金流DOMHRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率DOMHRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度DOMHRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率DOMHRGNX
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
